Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA ...
TipRanks on MSN
Biohaven price target lowered to $14 from $28 at Citi
Citi lowered the firm’s price target on Biohaven (BHVN) to $14 from $28 and keeps a Buy rating on the shares. The firm cites the complete response ...
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.
Earlier this month, Biohaven Ltd. announced it received a Complete Response Letter from the FDA declining approval of its drug candidate VYGLXIA (troriluzole) for spinocerebellar ataxia, prompting the ...
cSorbonne Université, Institut, Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, University Hospital ...
Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.
The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...
Biohaven (BHVN) stock plunges as the FDA declines to approve its lead drug Vyglxia (troriluzole) targeted at spinocerebellar ataxia. Read more here.
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback